Related Experiment Video
Updated: May 15, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
[Glycemic targets and cardiovascular morbi-mortality]
Lyse Bordier1, Bernard Bauduceau
1Hôpital d'instruction des Armées Bégin, service d'endocrinologie, 94160 Saint-Mandé, France. lbordier@club-internet.fr
Presse Medicale (Paris, France : 1983)
|January 5, 2013
Summary
Intensive diabetes treatment shows mixed results; focus on individualizing care and controlling cardiovascular risk factors is key for type 2 diabetes management. Early intervention and avoiding hypoglycemia are crucial.
Area of Science:
- Endocrinology
- Diabetology
- Cardiovascular Medicine
Background:
- Previous studies (UKPDS, DCCT) indicated intensive treatment reduced microvascular and macrovascular events in diabetes.
- Recent trials (ACCORD, ADVANCE, VADT) presented varied outcomes, including increased mortality with intensive therapy in type 2 diabetes.
Purpose of the Study:
- To analyze post-2008 studies on diabetes management and extract lessons for clinical practice.
- To inform individualized glycemic targets and treatment strategies for type 2 diabetes.
Main Methods:
- Review and analysis of clinical studies published since 2008 concerning diabetes treatment.
- Consideration of factors influencing glycemic control and cardiovascular risk.
Main Results:
- Glycemic memory is present, but tensional memory is absent.
- Control of all cardiovascular risk factors is essential.
- Early diabetes treatment is necessary, but intensive therapy should be approached cautiously to avoid hypoglycemia.
Conclusions:
- Individualized glycemic targets and treatment plans are recommended, considering patient-specific factors like age, diabetes duration, and comorbidities.
- Management of type 2 diabetes requires early, cautious intensive treatment combined with strict cardiovascular risk factor control.
- Recent guidelines (ADA, EASD) emphasize personalized approaches to diabetes care.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...